2025
Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance—India, 2018–2020
Tamilzhalagan S, Justin E, Selvaraj A, Venkateswaran K, Sivakumar A, Chittibabu S, McLaughlin H, Moonan P, Smith J, Suba S, Narayanan M, Ho C, Kumar N, Tripathy S, Shanmugam S, Hall-Eidson P, Ranganathan U. Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance—India, 2018–2020. Frontiers In Microbiology 2025, 15: 1515627. PMID: 39845030, PMCID: PMC11750862, DOI: 10.3389/fmicb.2024.1515627.Peer-Reviewed Original ResearchPZA resistancePyrazinamide resistanceMultidrug resistanceDuration of tuberculosis treatmentWhole-genome sequencingPrevalence of mutationsSecond-line drugsPZA-resistant isolatesResistance-conferring mutationsGenome sequenceTB burden countriesLineage 2Genotypic characterizationResistance markersNovel mutationsPhenotypic resistanceMutational diversityDiagnostic accuracyTuberculosis treatmentAntituberculosis drugsCo-resistanceBurden countriesPyrazinamideMutationsTB prevention
2017
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00498-16. PMID: 27956422, PMCID: PMC5328532, DOI: 10.1128/aac.00498-16.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsBayes TheoremBiological AvailabilityComputer SimulationDrug Administration ScheduleDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFluoroquinolonesHumansMicrobial Sensitivity TestsModels, StatisticalMycobacterium tuberculosisPyrazinamideRifampinTuberculosis, PulmonaryConceptsCompanion drugsExtensively Drug-Resistant TuberculosisSecond-line treatmentFirst-line treatmentSecond-line regimensDrug-resistant tuberculosisUse of pyrazinamideExtensive drug resistanceDrug resistance dataEmergence of strainsEmergence of mutationsXDR-TBSequential regimensHIV infectionAlternative drugsResistance amplificationPyrazinamide resistanceProlonged treatmentCombination antimicrobialsDrug resistanceInfectious diseasesPrevalenceProportion of simulationsAppropriate useRegimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply